比利时合成卡西酮:涉及α-吡咯烷基异己苯酮(α-PiHP)的多药中毒聚集性病例
该研究对比利时相邻地区三家医院报告至国家早期预警系统的α-PiHP相关中毒病例进行回顾性 convenience cluster 分析,共39例,采用标准化实验室方案进行毒物筛查。37份尿样分析确认α-PiHP,2份血样无法区分α-PiHP与α-吡咯烷基己苯酮。16份尿样定量显示α-PiHP浓度范围为1.0 μg/L至1,366.0 μg/L。记录到的临床症状包括焦虑、攻击、自杀意念、精神病性症状、言语含糊和意识下降。作者指出症状与既往合成卡西酮中毒相符,但α-PiHP存在与中毒严重度无相关性,且因存在多种其他物质,症状不能完全归因于α-PiHP。
要点
- 39例多药中毒聚集病例中37份尿样分析确认α-PiHP,2份血样无法区分α-PiHP与α-吡咯烷基己苯酮。
- 16份尿样定量显示α-PiHP浓度范围为1.0 μg/L至1,366.0 μg/L。
- 记录到的症状包括焦虑、攻击、自杀意念、精神病性症状、言语含糊和意识下降。
- 未发现α-PiHP存在与中毒严重度之间的相关性。
- 合成卡西酮在低至5-10 mg剂量即有 potency,因可得性、低成本和高效力而持续流行。
适用人群与场景
- 比利时相邻地区三家医院报告至国家早期预警系统的涉及α-PiHP的中毒病例,共39例,为多药中毒聚集病例。
研究设计与关键结果
- 研究类型为回顾性 convenience cluster 分析,共39例,来自比利时相邻地区三家医院,通过国家早期预警系统触发。
- 37份尿样分析确认α-PiHP;2份血样无法区分α-PiHP与α-吡咯烷基己苯酮。
- 16份尿样定量显示α-PiHP浓度范围为1.0 μg/L至1,366.0 μg/L。
- 记录到的临床症状包括焦虑、攻击、自杀意念、精神病性症状、言语含糊和意识下降。
- 未发现α-PiHP存在与中毒严重度之间的相关性。
- 作者指出症状与既往合成卡西酮中毒相符,但因存在多种其他物质,不能完全归因于α-PiHP。
证据类型、等级与局限
- 证据类型:回顾性 convenience cluster 分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者强调需要积极的信息共享以改善医疗应对和对合成药物相关风险的认识。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Synthetic cathinones, known as 'gravel' or 'bath salts', include α-pyrrolidinoisohexiophenone and its analogues α-pyrrolidinovalerophenone and α-pyrrolidinohexanophenone; often referred to as 'flakka' on the street or 'zombie drug' in media reports. Documented motivation for use includes libido enhancement and appetite suppression. Since its international scheduling, α-pyrrolidinoisohexiophenone has gained prevalence in European Union countries where α-pyrrolidinovalerophenone previously dominated.
METHODS: Three Belgian hospitals in adjacent regions reported intoxications involving α-pyrrolidinoisohexiophenone to the national early warning system. This triggered a retrospective analysis of a convenience cluster of 39 cases. Toxicological screening was performed using standardised laboratory protocols. Patient data, encompassing demographics, drug use patterns, and clinical symptoms, were obtained from routine hospital records.
RESULTS: α-Pyrrolidinoisohexiophenone was analytically confirmed in 37 urine samples. The distinction between α-pyrrolidinoisohexiophenone and α-pyrrolidinohexanophenone was not possible for two blood samples. Urine samples quantification, (n = 16), revealed α-pyrrolidinoisohexiophenone concentrations ranging from 1.0 μg/L to 1,366.0 μg/L. A variety of clinical symptoms were recorded, including anxiety, aggression, suicidal thoughts, psychosis, babbling, and decreased consciousness.
DISCUSSION: Symptoms in this cluster matched those from previous synthetic cathinone intoxications. No correlation was found between α-pyrrolidinoisohexiophenone presence and intoxication severity. Synthetic cathinones remain popular due to their availability, low cost, and potency at doses as low as 5-10 mg, likely fuelling continued development of new analogues.
CONCLUSION: The cluster of patients with poly-drug intoxications involving α-pyrrolidinoisohexiophenone in Belgium highlights the challenges posed by synthetic cathinones. Symptoms such as agitation, hallucinations and aggression align with those seen in prior cases of bath salts, although they cannot be solely attributed to α-pyrrolidinoisohexiophenone due to the presence of multiple other substances. We provide insight into α-pyrrolidinoisohexiophenone poisoning and emphasize the need for active information sharing to improve healthcare responses and awareness of the risks associated with synthetic drugs.
参考来源
- Balcaen M, De Brabanter N, Verougstraete N, et al. Synthetic cathinones in Belgium: a cluster of poly-drug intoxications involving α-pyrrolidinoisohexiophenone (α-PiHP). Clin Toxicol (Phila). 2025. PMID: 40625199. doi:10.1080/15563650.2025.2523528
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。